Opdivo mechanism of action?

How does Opdivo (nivolumab) work?

Opdivo is a monoclonal antibody that blocks the immune checkpoint receptor PD-1 (programmed death-1) on T cells. By inhibiting PD-1, Opdivo helps keep T cells active so they can recognize and attack tumor cells [1].

What does blocking PD-1 change inside the immune system?

PD-1 normally acts as a brake that dampens T-cell activity. Tumors can exploit this pathway to reduce immune responses. When Opdivo blocks PD-1, it removes that inhibitory signaling, which can increase T-cell killing of cancer cells and support an anti-tumor immune response [1].

How does Opdivo compare with checkpoint drugs that target PD-L1?

Opdivo targets PD-1 directly. Drugs that target PD-L1 (the ligand for PD-1) prevent PD-1 signaling indirectly by blocking the PD-1/PD-L1 interaction. Both approaches aim to restore T-cell activity, but they differ in the specific molecule they bind [1].

Does Opdivo kill cancer directly?

Opdivo does not directly kill tumor cells like a traditional cytotoxic chemotherapy. Its effect is mediated through immune activation by blocking PD-1 on T cells [1].

What does the mechanism imply for combination therapy?

Because Opdivo acts by reactivating T cells, it is often combined with other treatments that can increase tumor immunogenicity or improve immune cell trafficking and killing. Those combinations are designed to strengthen the overall immune response beyond checkpoint blockade alone [1].

Sources

1. https://www.opdivo.com/about-opdivo/how-opdivo-works